AKT1 and small cell lung carcinoma: Mechanically, we found that circVAPA served as a ceRNA against miR-377-3p and miR-494-3p to weaken their inhibitory effects on IGF1R mRNA expression, thus promoting SCLC progression by activating the PI3K/AKT pathway.